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Background: Stereotactic body radiation therapy (SBRT)using intensity-modulated radiotherapy (IMRT) can be a safe
modality for treating spinal bone metastasis with enhanced targeting accuracy and an effective method for achieving
good tumor control and a rigorous pain response.
Methods/design: This is a single-center, prospective randomized controlled trial to evaluate pain relief after RT
and consists of two treatment groups with 30 patients in each group. One group will receive single-fraction
intensity-modulated RT with 1×24 Gy, and the other will receive fractionated RT with 10×3 Gy. The target parameters
will be measured at baseline and at 3 and 6 months after RT.
Discussion: The aim of this study is to evaluate pain relief after RT in patients with spinal bone metastases by means of
two different techniques: stereotactic body radiation therapy and fractionated RT. The primary endpoint is pain
relief at the 3-month time-point after RT. Secondly, quality of life, fatigue, overall and bone survival, and local
control will be assessed.
Trial registration: ClinicalTrials.gov identifier NCT02358720 (June 2, 2015).
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The vertebral column is the main localization of bone
metastases and is where they frequently indicate an ad-
vanced stage of a malignant primary disease [1, 2].
Two thirds of all patients with tumors are estimated to
develop bone metastases in the course of their disease
[3]. Spinal bone metastases are of central impact for
patients in a palliative setting. The clinical symptoms
include pain at rest and under exercise but also impaired
activity of daily life, the risk of pathological fractures, and
neurological deficits. Pain is the essential factor for
decreased quality of life (QoL) of patients with bone
metastases. In regard to pain therapy and re-calcification* Correspondence: harald.rief@med.uni-heidelberg.de
1Department of Radiation Oncology, University Hospital of Heidelberg, Im
Neuenheimer Feld 400, 69120 Heidelberg, Germany
Full list of author information is available at the end of the article
© 2015 Rief et al. This is an Open Access artic
(http://creativecommons.org/licenses/by/4.0),
provided the original work is properly credited
creativecommons.org/publicdomain/zero/1.0/of former osteolytic lesions, palliative radiotherapy (RT)
represents an effective treatment option [4]. The most
common schedule was specified as 30 Gy in 10 fractions.
The outcome showed a partial pain response in 50 % to
80 % of patients and a complete pain response in one third
[5]. Stereotactic body radiation therapy (SBRT) using
intensity-modulated radiotherapy (IMRT) can be a safe
modality for treating spinal metastasis with enhanced
targeting accuracy [6]. Secondly, IMRT to the spine
was well tolerated (especially in the spinal cord), had
no significant late toxicities, and spared other organs at
risk simultaneously [7]. Pretreatment megavoltage com-
puted tomography (CT) allows clinicians to position con-
trol and correction to determine the localization of the
metastasis, and to hold a divergence of the dose of the
local region most minimally [8]. Nguyen et al. [9] showed
that SBRT with 24 Gy is a safe and effective treatmentle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
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and palliation of pain associated with spinal metastases.
To the best of our knowledge, no comparable randomized
study has been described in the literature so far.
The aims of this study were to apply a high biological
dose in the tumor region and to achieve a comparable
result related to pain relief and local control on the one
hand and to reduce the overall treatment time for palliative
patients with painful spinal bone metastases on the other
hand. Secondly, the aim was to evaluate QoL, fatigue,
and survival.
Methods/design
This is a single-center, prospective randomized controlled
trial with parallel-group design to determine the pain relief
after RT in patients with spinal bone metastases. Two
different techniques were evaluated: high-dose single-
fraction IMRT with 1×24 Gy and fractionated external
beam RT with 10×3 Gy. Prior to enrolment in the study,
the patients will undergo a staging of the vertebral column
in connection with their CT for RT planning and magnetic
resonance imaging (MRI) to measure the spinal cord
dimension. After the baseline results have been recorded,
the patients will be randomly assigned to one of the two
groups: single-fraction IMRT 1×24 Gy (n = 30) or frac-
tionated RT 10×3 Gy (n = 30). The target parameters will
be measured and recorded at baseline, at the end of RT
(t1), and at 12 weeks (t2) and 6 months (t3) after the end of
the irradiation period (Fig. 1).
Recruitment and randomization
The patients will be given information on the study by
the medical personnel of the RT department in connection
with the planning of the RT schedule (about 1 to 2 weeks
prior to the start of RT). If they are interested in par-
ticipating in the study, the study candidates will be
given the patient information sheet, including the dec-
laration of informed consent, with the request that they
re-read the information carefully and, if they consent to
the conditions, return the signed declaration at the next... -1 0 1 …
t0 t1 (Radi
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Fig. 1 Flowchart of the study. CT, computed tomography; IMRT, intensity-moappointment. Patients will be given the opportunity to ask
the study staff further questions. Informed consent will be
obtained from each participant prior to enrolment in the
study. Among the preconditions for participation in the
study is the condition that no metastatic spinal cord com-
pression (tumor distance of more than 3 mm to spinal
cord) of the metastasized vertebral body be detected in
the MRI recorded during the planning procedure.
A block randomization procedure shall be used to ensure
the even distribution of patients into two intervention
groups, stratified at baseline by pain level. The patients shall
then be assigned 1:1 to one of the two treatment groups on
the basis of the baseline measurements. The randomization
procedure shall be carried out by a central office. The study
personnel responsible for the recruitment and baseline
measurements shall have no access to the randomization
list. The recruitment phase shall be concluded with the at-
tainment of the planned number of patients (60 patients in
total). It shall last 12 months and was scheduled to start in
December 2014. Regular study participation shall end 6
months after enrolment in the study or, where applicable,
with the respective patient’s death.
Inclusion criteria
 Patients with a histologically confirmed tumor
diagnosis and with secondary diagnosed solitary/
multiple spinal bone metastases
 Indication for RT of the spinal bone metastases
 Maximum of two irradiated vertebral bodies per
region
 Maximum of two different vertebral regions
 Age of between 18 and 80 years
 Karnofsky index [10] of at least 70
 Signed declaration of informed consent
 Tumor distance of more than 3 mm to spinal cord.
 Exclusion criteria
 Multiple myeloma or lymphoma
 Significant neurological or psychiatric disorders,
including dementia and epileptic seizures2 … 14 … 26
ation end) t2 t3
MRT 1 x 24 Gy
ionated RT 10 x 3 Gy
Anxiety t0 – t3
t0, t2
t0 – t3
dulated radiotherapy; MRI, magnetic resonance imaging; RT, radiotherapy
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 Previous RT at the current irradiation site
 Other severe disorders that in the judgment of the
study director may prevent the patient’s participation
in the study
 Lacking or diminished legal capacity
 Any medical of psychological condition that the study
director considers a preventive factor for the patient’s
ability to complete the study or to adequately
understand the scope of the study and to give his or
her consent.Assessment of the primary and secondary endpoints
The aim of the trial is to evaluate pain relief after RT in
patients with spinal bone metastases. Two different tech-
niques are evaluated: single-fraction IMRT with 1×24 Gy
and fractionated external beam RT with 10×3 Gy. The
primary endpoint is defined as pain relief of more than 2
points according to visual analog scale (VAS) measured
at the irradiated region at the 3-month time-point after
the end of RT (t2). Secondary endpoints are QoL, fa-
tigue, pain, overall survival, bone survival, local control,
pathological fracture, and neurological deficit. The base-
line examination shall be carried out on the first day of RT
prior to the start of therapy and is scheduled to comprise
the comprehensive recording of the socio-demographic
data, the recording of the current pain situation, the fear
of suffering fractures, the QoL, and the current degree of
fatigue. The follow-up examinations shall take place after
the end of RT (day of the last fraction) and 12 weeks and
6 months after RT, measuring those parameters recorded
at the baseline examination. The further follow-up exami-
nations shall correspond to those carried out as standard
after-care investigations.
The secondary endpoints such as fatigue, QoL, and
anxiety shall be recorded by using validated questionnaires
(EORTC QLQ FA13 [11], EORTC QLQ BM22 [12], and
the questionnaire to record stress in patients with cancer
(FBK) according to Book et al. [13]). All patients will also
be asked to record their pain history by using a pain diary
(documentation of medication daily during treatment, once
weekly after the end of treatment, VAS pain scale). Further-
more, the local control is assessed by means of CT images
taken prior to and 3 and 6 months after RT. The pain re-
sponse is documented on the VAS (range of 0 to 10).
Complete response is defined as VAS score of 0 after 3
and 6 months, and partial response is defined as a score
improvement by at least 2 points after 3 and 6 months,
according to the international consensus response cat-
egories of Chow et al. [14]. Overall survival is defined as
time from initial diagnosis until death, and bone survival
is defined as time from initial diagnosis of spinal bone me-
tastasis until death.Radiotherapy
Treatment is simulated with a CT simulator by using a
3-mm slice thickness taken within the involved vertebral
region. Immobilization is ensured with an Aquaplast
head mask (Aquaplast Corporation, Wyckoff, NJ, USA),
vacuum mattress, and Wingstep® (Elekta, Stockholm,
Sweden). On the basis of the planning CT, risk organs
and clinical target volume (CTV) are contoured. The
spinal cord is contoured on the basis of visible target on
the CT scan with the help of fusion with MRI. CTV
confirmed planning target volume (PTV). The dose of
PTV occurred at the 80 % isodose, encircling the PTV.
The RT procedure in group A is conducted as IMRT
(tomotherapy or step-and-shoot IMRT or volumetric
modulated arc therapy) 24 Gy in a single fraction at the
80 % isodose. In group B, RT is performed as irradi-
ation of the involved vertebral body as well as the ones
immediately above and below to a total dose of 30 Gy
with a single daily dose of 3 Gy using 6 MV individually
formed beams (Linac, multileaf collimator) after CT
scan-based 3D planning. The same tolerance doses of the
organs at risk as in the RTOG 0631 study are used [15].
Therapy drop-out criteria
 At the patient’s wish
 Medical condition requiring the discontinuation of
therapy in the opinion of the study director or
patient
 Insufficient compliance
 Medical or ethical aspects that make it impossible to
continue the study
 Participant recruiting difficulties that involve an
unreasonable prolongation of the study duration
 Adverse reactions that have not yet been reported in
their form, severity, duration, and impact
 Unexpectedly high incidence of already-known adverse
reactions
 By official decision.
Statistical analysis
The total number of patients undergoing RT in the
Department of Radiation Oncology at the University
Hospital Heidelberg for metastatic processes in the
vertebral column in the recruitment period is about
120, and about 90 of them shall fulfill the inclusion
criteria within 1 year. On account of the explorative
character of this study, it is not possible to estimate
the total number of cases; however, with a scheduled
number of 30 patients per group, it will be possible to
detect a standardized mean value effect of 0.74 with a
power of 80 % and a significance level of 5 % when a
normal distributed variable is examined. The primary
endpoint is a categorical variable (the percentage of
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according to the VAS). Means, standard deviations,
medians, and minimum and maximum or absolute and
relative frequencies will be reported according to the scale
level of the variables. The results will be reported as P
values. For all analyses, a P value of 0.05 or less will be
considered significant, and results of appropriate statistical
tests will be of a descriptive nature and have no con-
firmatory value. Wherever possible, statistical graphics
will illustrate the findings.
Ethical issues, information, and safety
The study protocol, patient information sheet, and
declaration of informed consent were submitted to the
Heidelberg University Ethics Committee. Approval was
given in 2013 (#S-431/2013). Additionally, approval was
given from the federal office of radiation protection in
Germany. Insurance for recruited patients was provided.
The study directors shall immediately notify the Ethics
Committee of any study protocol changes that may have
an impact on the safety of the patients. Furthermore, the
Ethics Committee shall be notified of all severe adverse
events reported to the study directors and of the regular
or premature termination of the study. The procedures
described in the submitted study protocol regarding the
performance, evaluation, and documentation of this study
were selected in such a way that the principles of the
Good Clinical Practice guidelines are observed. The
regulations regarding medical confidentiality and data
protection are fulfilled.
Discussion
The aim of this explorative study is to evaluate in a
randomized fashion the pain relief of two different RT
techniques. A comparable study was recently conducted
without randomization [15]. QoL, fatigue, local control,
and survival are secondary endpoints. Bone metastases are
a very frequent secondary diagnosis associated with ad-
vanced tumor disease, and the vertebral column is the
most frequent localization [16, 17]. Spinal bone metastases
are an important factor related to QoL in an advanced
tumor stage. Patients affected by this condition are usually
immobilized and this is due primarily to the risk of
pathological fractures and the related risk of spinal
cord compression. Palliative percutaneous RT is one of
the most important therapeutic options available in this
regard. Therapy goals are a reduction in pain and fatigue,
improvement of QoL, and prevention of pathological frac-
tions or neurological deficits. Recent trials demonstrated
the feasibility and accurate use of SBRT to treat spinal
metastases, with rigorous quality control, in a cooperative
group setting. This technique allows the application of a
high dose at the tumor region in the localized spine. The
spinal cord is the dose-limiting organ at risk for SBRT.Radiation myelopathy usually occurs more than 6 months
but fewer than 3 years after the end of the treatment [18].
Stereotactic radiosurgery delivers a highly conformal
radiation dose to a small target in a single fraction with a
sharp fall-off in the surrounding areas. The aims of this
explorative study are to investigate pain relief after con-
ventional fractionated RT and single-fraction IMRT and to
evaluate local control and overall and bone survival and
also to assess other clinical parameters such as pain, QoL,
and fatigue as secondary endpoints. On the basis of this
study, if pain relief and local control are superior in the
single-dose group and there are no side effects, the results
would offer a rationale for future large controlled studies
as non-inferiority trials to confirm these findings.
Trial status
This trial is currently recruiting.
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